πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12428480

Anti-CD19 antibodies and multi-specific binding proteins

Cullinan Therapeutics, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12427173

Use of bacteria, bacterial products, and other immunoregulatory entities in combination wi

Biomed Valley Discoveries, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12428487

Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide an

Dyne Therapeutics, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12427201

Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor ant

Sutro Biopharma, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12421308

Anti-G-CSF antibodies and uses thereof

ME Therapeutics Inc. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12421292

Anti-DLL3 chimeric antigen receptors and uses thereof

Legend Biotech Ireland Limited Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12421317

Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12415867

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12403167

Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof

OCEAN UNIVERSITY OF CHINA Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12398123

Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflam

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12391750

Anti-C1S antibodies and methods of use thereof

Bioverativ USA Inc. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12391742

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12384845

Activatable masked anti-CTLA4 binding proteins

Xilio Development, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12384853

Anti-HER2/PD1 bispecific antibody

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12383572

Administration of an anti-activin-a compound to a subject

Atara Biotherapeutics, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12378193

Anti-arrhythmicity agents

The Regents of the University of California Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12377068

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pe

Provectus Pharmatech, Inc. Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12371499

Method of treating cancer using anti-AV8 antibodies

The Regents of the University of California Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12371506

Subcutaneous administration of anti-CD38 antibodies

Takeda Pharmaceutical Company Limited Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12370264

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide an

Dyne Therapeutics, Inc. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12371434

MLL1 inhibitors and anti-cancer agents

CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12365729

Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

Disc Medicine, Inc. Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12365723

Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS

Takeda Pharmaceutical Company Limited Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357617

Discovery of novel anti-infectives for gram negative pathogens

The Regents of the University of California Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted